EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

Intraperitoneal CAR T-cell therapy for peritoneal carcinomatosis from gastroesophageal cancer: preclinical investigations to a phase I clinical trial (NCT06623396)

David Restle, Alfredo Amador-Molina, Kyohei Misawa, Srijita Banerjee, Geoffrey Ku, Prasad S Adusumilli

Journal for ImmunoTherapy of Cancer · 2025-09 · 13 (9) · e012292

DOI: 10.1136/jitc-2025-012292 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 15.09.2025. Verfasst von David Restle und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Thoracic Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Peritoneal Neoplasms, Immunotherapy, Adoptive, Stomach Neoplasms, Esophageal Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, DOD Peer Reviewed Cancer Research Program, Commonwealth Foundation for Cancer Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peritoneal carcinomatosis is a frequent metastatic condition in gastroesophageal cancer and is associated with poor prognosis and limited therapeutic options. Here, we establish clinically relevant mouse models of peritoneal carcinomatosis to evaluate the efficacy of a second-generation mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy. Our model recapitulates key clinical features, including ascites, bowel obstruction, and an immunosuppressive tumor microenvironment characterized by tumor-cell programmed death-ligand 1 expression and elevated TGF-β levels in ascites. To overcome T-cell exhaustion, we engineered a CAR T-cell construct (M28z1XXPD1DNR) that incorporates a programmed cell death protein-1 decoy receptor lacking the intracellular signaling domain, which enhances functional persistence. We demonstrate that intraperitoneal (regional) administration of CAR T cells at low doses achieves superior antitumor efficacy, longer survival, and sustained functional persistence, compared with intravenous (systemic) administration. Of note, intraperitoneal treatment also exhibits potency against distant disease sites. These findings provide a strong rationale for clinical translation; we are now conducting a clinical trial ( NCT06623396 ) to evaluate intraperitoneal administration of M28z1XXPD1DNR CAR T cells in patients with gastroesophageal cancer peritoneal carcinomatosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peritoneal NeoplasmsImmunotherapy, AdoptiveStomach NeoplasmsEsophageal NeoplasmsReceptors, Chimeric AntigenT-LymphocytesAnimalsHumansMiceFemaleMesothelinMale

Stichwörter der Autor:innen

Adoptive cell therapy - ACTChimeric antigen receptor - CAREsophageal CancerT cell

Substanzen

Receptors, Chimeric AntigenMesothelin

Autor:innen und Institutionen

  • Department of Surgery, Thoracic Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Surgery, Thoracic Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA adusumip@mskcc.org.
  • Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Förderung

  • NCI NIH HHS
  • DOD Peer Reviewed Cancer Research Program
  • Commonwealth Foundation for Cancer Research Foundation
  • Baker Street Foundation
  • Center for Experimental Therapeutics of Memorial Sloan Kettering Cancer Center
  • Novocure
  • Esophageal Cancer Education Fund
  • National Institutes of Health

Zitieren

APA

Restle, D., Amador-Molina, A., Misawa, K., Banerjee, S., Ku, G., & Adusumilli, P. S. (2025). Intraperitoneal CAR T-cell therapy for peritoneal carcinomatosis from gastroesophageal cancer: preclinical investigations to a phase I clinical trial (NCT06623396). Journal for ImmunoTherapy of Cancer, 13(9), e012292. https://doi.org/10.1136/jitc-2025-012292

Vancouver

Restle D, Amador-Molina A, Misawa K, Banerjee S, Ku G, Adusumilli PS. Intraperitoneal CAR T-cell therapy for peritoneal carcinomatosis from gastroesophageal cancer: preclinical investigations to a phase I clinical trial (NCT06623396). Journal for ImmunoTherapy of Cancer. 2025;13(9):e012292. doi:10.1136/jitc-2025-012292

BibTeX
@article{Restle2025,
  author = {Restle, David and Amador-Molina, Alfredo and Misawa, Kyohei and Banerjee, Srijita and Ku, Geoffrey and Adusumilli, Prasad S},
  title = {Intraperitoneal CAR T-cell therapy for peritoneal carcinomatosis from gastroesophageal cancer: preclinical investigations to a phase I clinical trial (NCT06623396)},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {9},
  pages = {e012292},
  doi = {10.1136/jitc-2025-012292}
}
Kostenlos starten →